

References

I-272

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/>
2. Rystiggo® (rozanolixizumab-noli) injection, for subcutaneous use. [package insert]. UCB, Inc. Smyrna, GA. 06/2023.
3. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Rozanolixizumabnoli.
4. Micromedex DrugDex Compendium®. 2023. Rozanolixizumab-noli
5. Rozanolixizumab-noli. Lexi-Drugs. Lexicomp Online. Lexicomp; 2023.
6. Bril V, Benatar M, Anderson H, et al. Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial. *Neurology*. 2021;96:e853-e865.
7. Bril V, Druzdz A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalized myasthenia gravis (MycarinG): a randomized, double-blind, placebo controlled, adaptive phase 3 study. *Lancet Neurol*. 2023;22:383-94.
8. Kiessling P, Lledo-Garcia R, Watanabe S, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. *Sci Transl Med*. 2017;9(414):1-12.